Echo Therapeutics Announces Strategic Partnership with Medical Technologies Innovation Asia (MTIA)
Echo to receive a $10 million cash investment from MTIA and Platinum Partners Company will withdraw the offering identified in recent Form S-1 filing Echo Therapeutics, Inc. (ECTE) ("Echo"), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that it entered into a strategic collaboration agreement with Medical Technologies Innovation Asia (MTIA), Ltd., Hong Kong, for a license arrangement and equity investment in Echo.
1st Detect Awarded U.S. Patent for Novel Mass Spectrometer Design
1st Detect Corporation, a subsidiary of Astrotech Corporation (ASTC), announced today that the United States Patent Office ("USPTO") has allowed the issuance of a key patent for the company's unique ion trap used for chemical analysis and detection. "We are extremely pleased that the USPTO has allowed this patent. This patent is an important component of our intellectual property portfolio as it allows 1st Detect to enhance the performance of miniaturized mass spectrometers without an increase in size or cost," said Thomas B Pickens III, Chairman and CEO of 1st Detect. "The patent clearly validates our technology, while both demonstrating and protecting the progress we have made in the development of the 1st Detect mass spectrometer."
BG Medicine Welcomes Final Determination by CMS of 2014 Reimbursement for BGM Galectin-3(R) Test
BG Medicine, Inc. (BGMD) announced today that the Centers for Medicare and Medicaid Services (CMS) have published the final determination of the 2014 Medicare national limitation amount for the Company's galectin-3 blood test (analyte-specific CPT(R) Code 82777) at the amount of a crosswalked test (analyte-specific CPT(R) Code 84244) whose 2014 national limitation amount is $30.01. This national limitation amount will replace the galectin-3 blood test's national limitation amount of $17.80 that was effective in 2013.
"We are very pleased that CMS has finalized the previously announced preliminary determination of the Medicare reimbursement rate for our galectin-3 test," said Dr. Paul R. Sohmer, President and Chief Executive Officer of BG Medicine.
CytRx Reports Highly Statistically Significant Positive Results from its Global Phase 2b Clinical Trial
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced highly positive top-line efficacy results from a multicenter, randomized, open-label global Phase 2b clinical trial. The trial investigated the efficacy and safety of aldoxorubicin compared with doxorubicin in subjects with first-line metastatic, locally advanced or unresectable soft tissue sarcomas (STS). Aldoxorubicin combines the chemotherapeutic agent doxorubicin with a novel linker-molecule that binds specifically to albumin in the blood to allow for delivery of higher amounts of doxorubicin (3½ to 4 times) without the major dose-limiting toxicities seen with administration of doxorubicin alone.
LED Medical Announces US Distribution Agreement with Benco Dental
LED Medical Diagnostics Inc. ("LED Medical" or the "Company") (TSX VENTURE:LMD)(LEDIF)(LME.F) is pleased to announce that its wholly-owned subsidiary, LED Dental Inc. ("LED Dental"), has entered into a non-exclusive partnership with Benco Dental ("Benco") for the distribution of the Company's VELscope® Vx Enhanced Oral Assessment System and product line within the United States market.
"We are pleased to partner with Benco for distribution in the United States," stated Dr. David Gane, CEO for LED Medical. "Benco currently serves more than 35,000 customers across the country and maintains an excellent reputation in the dental industry. We are excited about the opportunity to work together, maximizing the significant sales potential for the VELscope® Vx product line through its extensive network."
NeuroMetrix to Partner with Omron Medical Devices for Distribution of NC-stat DPNCheck in China
NeuroMetrix, Inc. (NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, announced that it had entered into an agreement with Omron Medical Devices, a subsidiary of Omron Healthcare China, to be the exclusive distributor for NC-stat® DPNCheck® in China. Earlier this year NeuroMetrix and Omron Healthcare Co. Ltd. announced a partnership for the exclusive distribution of NC-stat DPNCheck in Japan.
NC-stat DPNCheck is a rapid, accurate and quantitative point-of-care test for early detection of diabetic peripheral neuropathy (DPN), which affects over half of people with diabetes. DPN causes significant morbidity including pain, increased risk of falling in the elderly, and is the primary trigger for diabetic foot ulcers which may require lower extremity amputations.
Rambus and Micron Sign License Agreement
Agreement settles all outstanding disputes
Rambus Inc. (RMBS) and Micron Technology, Inc. (MU) today announced they have signed a broad patent cross license agreement. Under the agreement, Micron gains the right to use any Rambus patent for the manufacture of specified integrated circuit products, including any memory integrated circuit products. Certain of these memory products will enjoy a perpetual, paid-up license after the end of the initial term. The agreement requires quarterly royalty payments to Rambus over the next seven years capped at $10 million per quarter, with a rolling twelve-month cap fixed at $40 million, or $280 million during the initial term. In addition, Micron will have the option to extend the initial term of this agreement for additional renewal periods. As part of this agreement, the two companies have settled all outstanding patent and antitrust claims, and the agreement covers both Micron and Elpida products. Other terms and details of the agreement are confidential.
Synthetic Biologics Enters into License with Cedars-Sinai Medical Center to Develop Novel Anti-infective Approaches for Irritable Bowel Syndrome (IBS), Obesity and Diabetes
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infectious diseases and other diseases, announced today that it entered into worldwide license and option agreements with Cedars-Sinai Medical Center ("Cedars-Sinai") for the development of new treatment approaches to target non-bacterial intestinal microorganism life forms known as archaea that are associated with intestinal methane production and chronic diseases such as irritable bowel syndrome (IBS), obesity and type 2 diabetes, through its newly formed subsidiary, Synthetic Biomics, Inc.
Prana Completes PBT2 Dosing in IMAGINE Alzheimer's Disease Clinical Trial
95% Patient Retention Level Achieved in IMAGINE Trial
Prana Biotechnology (ASX: PBT) (NASDAQ: PRAN), a developer of best-in-class treatments for neurodegenerative disease, today announced the completion of the treatment phase of its IMAGINE Alzheimer's Disease (AD) clinical trial.
There were 42 patients with prodromal or mild AD enrolled in the Phase II double-blind placebo-controlled clinical trial of Prana's novel drug, PBT2. A total of 40 patients completed the planned 12 months of treatment with PBT2, or placebo, bringing the treatment phase of the trial to a close.
OncoMed and Celgene Announce Strategic Collaboration Advancing Multiple Anti-Cancer Stem Cell Therapeutics to Offer Potential Benefits to Cancer Patients
Celgene Invests in OncoMed's Demcizumab and up to Five Additional Preclinical Biologics Programs; OncoMed Leads Early Clinical Trials and Retains Co-Development, Co-Commercialization and Profit-Sharing Rights
OncoMed to Receive $177.25 Million Upfront, Including a $22.25 Million Equity Investment
OncoMed Pharmaceuticals, Inc. (OMED) and Celgene Corporation (CELG) today announced an agreement to jointly develop and commercialize up to six anti-cancer stem cell (CSC) product candidates from OncoMed's biologics pipeline, including demcizumab (OMP-21M18, Anti-DLL4).
Passport Energy Ltd. Announces Additional Land Acquisition Details
Passport Energy Ltd. (PPO - TSX Venture, PPOZF - OTC),("Passport") provides, further to its news release dated November 27, 2013, the following additional details of the previously announced land acquisition.
Passport has entered into an agreement with a private oil and gas company to acquire 22 1/4 contiguous sections (5,760 acres) of 100% owned land in the Hardy area of SE Saskatchewan for $600,000 cash. The acquisition will be subject to certain conditions including Passport completing due diligence on the properties, obtaining a satisfactory title opinion on the properties, completing a financing, and completing the formal agreement between Passport and the vendor.
Passport Energy Ltd. Announces Land Acquisition
Passport Energy Ltd. (PPO - TSX Venture), ("Passport") advises that it has entered into an agreement with a private oil and gas company to acquire 22 1/4 contiguous sections (5,760 acres) of 100% owned land in the Hardy area of SE Saskatchewan. The acquisition price will, subject to certain conditions being met, be paid by Passport in cash. Passport believes the acreage is located in a more prospective area of the new light oil Bakken play trend that it has been exploring for the past 2 years.
Passport Energy Ltd. Announces 51-101 Reserve Report and Production Update
Passport Energy Ltd. (PPO - TSX Venture), ("Passport" or the "Company") is pleased to announce that it has filed its 51-101 reserve report on its reserves in the Hardy area of SE Saskatchewan.
Corporate Reserve Update
GLJ has assigned Passport, total proved company interest reserves of 49,000 bbls (166,000 gross bbls), representing an 81% increase in the company's total proved reserves when compared to last year's evaluation.
ARIAD Announces Positive Opinion by the European Medicines Agency on the Continued Availability of Iclusig in Patients with Leukaemias
Recommendations made to minimize risk of occlusive vascular events
ARIAD Pharmaceuticals, Inc. (ARIA) today announced adoption of a positive opinion by the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA) on the continued availability of Iclusig® (ponatinib) in the EU for use in patients in its authorized indications. Following its review of updated clinical-trial data on Iclusig, the CHMP made a series of recommendations on measures to help minimize the risk of occlusive vascular events in patients taking Iclusig. The authorized indications of Iclusig, as approved in July 2013, are as follows:
Inovio Pharmaceutical's DNA Vaccine for the Deadly MERS Virus Induces Robust Immune Response in Preclinical Trial
No vaccine exists for the MERS virus that has killed 42% of those infected
Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that preclinical testing of a DNA synthetic vaccine for the virulent Middle East Respiratory Syndrome coronavirus (MERS) induced robust and durable immune responses, demonstrating the potential for a SynCon® DNA vaccine to prevent and treat this deadly virus.
Since 2012, when the virus was first identified, 153 cases from nine Middle Eastern countries have been reported and, alarmingly, 42% of these cases have been fatal.
NovaBay Pharmaceuticals Announces Publication of Novel Surgical Procedure for Life Threatening Wounds and Flesh Eating Bacteria
New Procedure Utilizes Adjunctive NeutroPhase® Therapy Paper in the Medical Journal WOUNDS Describes First Successful Procedure that Removes Toxins from Wounds with Less Invasive Debridement and Avoids Possible Amputation
NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a clinical-stage biopharmaceutical company developing topical non-antibiotic antimicrobial products, today announced the publication of a scientific paper by Dr. John R. Crew of Seton Medical Center, Daly City, California, describing the first use of adjunctive NeutroPhase®* irrigation therapy in conjunction with Negative Pressure Wound Therapy (NPWT) to successfully manage the severely-infected wound in the arm of a patient with life-threatening ‘flesh-eating’ disease.
Horizon Pharma Announces Agreement to Acquire U.S. Rights to VIMOVO(R) and Provides 2014 Guidance
Horizon to Host Conference Call / Webcast Today at 8:00 a.m. EST
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that it has entered into an agreement to acquire from AstraZeneca AB the U.S. rights to VIMOVO® (naproxen/esomeprazole magnesium) delayed-release tablets, further expanding Horizon's focus on key primary care physician targets in the U.S. VIMOVO is approved in the U.S. to relieve the signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis and to decrease the risk of stomach (gastric) ulcers in patients at risk of developing stomach ulcers from treatment with NSAIDs. AstraZeneca will retain ex-U.S. rights to VIMOVO.
Spherix Announces Settlement Agreement and Continued Monetization of Patent Portfolio
Spherix Incorporated (SPEX) -- an intellectual property development company committed to the fostering and monetization of intellectual property, announced today that its wholly owned subsidiary, CompuFill LLC, has entered into a settlement and license agreement with a leading technology company.
This is the first settlement and license agreement for the CompuFill portfolio since Spherix acquired North South Holdings Inc. in September of 2013. Ongoing infringement enforcement continues as Spherix's model of patent monetization grows in both scope and size.
The CompuFill patents, each in the "on-line pharmacy automated refill system" sector, trace priority back to October 1997.
Intellipharmaceutics / Par to Make Immediate Commercial Launch of 15 and 30 mg Generic Focalin XR(R)
-- FDA Issues Final Approval of 15 mg, With 180 Days of Exclusivity, and 30 mg; and -- Tentative Approvals for the Company's 5, 10, 20 and 40 mg Strengths
Intellipharmaceutics International Inc. (IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company") a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs today announced that the U.S. Food and Drug Administration ("FDA") has granted final approval of the Company's dexmethylphenidate hydrochloride extended-release capsules for the 15 and 30 mg strengths. Commercial sale of these strengths will be launched immediately by the Company's commercialization partner in the United States Par Pharmaceutical, Inc. ("Par").
Discovery of a Conventional Natural Gas Reservoir in the Lower St. Lawrence Area
Petrolympic Ltd. ("Petrolympic" or the "Company") (TSX VENTURE:PCQ) is pleased to announce the discovery of a conventional reservoir of natural gas on its joint venture property in the Lower St. Lawrence area (the "Property") located in the Appalachian Basin of Quebec, which was announced by the Operator, Ressources & Energie Squatex Inc., ("Squatex") in its press release dated November 15, 2013 (see www.sedar.com). The Company holds an interest in 217,370 hectares (536,941 acres) of the Property through a joint venture with Squatex.